Indomethacin-guided cancer selective prodrug conjugate activated by histone deacetylase and tumour-associated protease

Joo Hee Jang, Hoyeon Lee, Amit Sharma, Sang Min Lee, Tae Hoon Lee, Chulhun Kang, Jong Seung Kim

Research output: Contribution to journalArticlepeer-review

38 Citations (Scopus)

Abstract

An indomethacin-guided drug delivery conjugate (IGDDC) has been designed by utilizing cancer associated elevated HDAC and CTSL activities as consecutive demasking ventures for drug activation. IGDDC exhibited preferential uptake by COX-2 positive cells both in vitro and ex vivo highlighting indomethacin's role in designing new cancer-specific drug delivery frameworks.

Original languageEnglish
Pages (from-to)9965-9968
Number of pages4
JournalChemical Communications
Volume52
Issue number64
DOIs
Publication statusPublished - 2016

Bibliographical note

Funding Information:
This work was supported by CRI (No. 2009-0081566, JSK), NRF (No. 2015R1A5A1037656, CK), the Basic Science Research Program (No. 20100020209, CK) project grants fromthe National Research Foundation of Korea.

Publisher Copyright:
© 2016 The Royal Society of Chemistry.

ASJC Scopus subject areas

  • Catalysis
  • Electronic, Optical and Magnetic Materials
  • Ceramics and Composites
  • General Chemistry
  • Surfaces, Coatings and Films
  • Metals and Alloys
  • Materials Chemistry

Fingerprint

Dive into the research topics of 'Indomethacin-guided cancer selective prodrug conjugate activated by histone deacetylase and tumour-associated protease'. Together they form a unique fingerprint.

Cite this